A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Daiichi Sankyo Ordered to Pay 8% Royalty to Seagen in ADC Patent Row
Daiichi Sankyo said on October 18 that it has been ordered by a Texas court to pay an 8% royalty on its antibody-drug conjugate (ADC) to Seagen, in addition to a previous award of US$41.8 million in damages, in their…
To read the full story
Related Article
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Daiichi Sankyo Wins ADC Patent Row against Seagen, Appeals Unfavorable Ruling in Enhertu Suit
November 21, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
- US Arbitrator Rejects Seagen’s Claims against Daiichi Sankyo in ADC Feud
August 16, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
- Jury Finds Enhertu Infringes Seagen Patent, Awards US$41.8 Million in Damages
April 12, 2022
BUSINESS
- ASKA/Veneno Tie Up for Discovery of Ion Channel Therapies
January 15, 2025
- Kyorin, Biodol Ink Option Deal for Novel Pain Drug
January 15, 2025
- Nippon Shinyaku Grabs Rights to Regenxbio’s MPS Gene Therapies
January 15, 2025
- Chugai to Transfer Tarceva to Cheplapharm in April
January 15, 2025
- Daiichi Buys IP Rights to Glycotope’s TA-MUC1 Antibody
January 15, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…